Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GLYATL1B encodes a putative acyltransferase, predicted to transfer an acyl group to the N-terminus of glutamine using phenylacetyl-CoA as an acyl donor[3]. It is related to the glycine N-acyltransferase gene family, but has scant direct evidence regarding its biological activity, clinical relevance, or disease association outside of database annotations. Its Ensembl ID is ENSG00000255151, HGNC ID is 37865, and the NCBI Gene ID is 100287520[3]. Some sources refer to GLYATL1B as a pseudogene (GLYATL1P3)—indicating it may not encode an active protein, but this is not fully clarified. In summary, GLYATL1B is annotated as a member of the glycine N-acyltransferase family, predicted to participate in the glutamine metabolic process, and currently lacks strong experimental evidence for being an actionable therapeutic target or a validated disease biomarker[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycine-N-acyltransferase like 1B (GLYATL1B).